Previous 10 | Next 10 |
Summary Dr. Reddy's Laboratories is seeing its push into the generics market bear some fruit. However, RDY is also seeing a 23% decline in sales in key segments, due to a drop-off in Sputnik vaccine sales. The decline of COVID related products and the refocusing to new generic...
Dr. Reddy's Laboratories Limited (RDY) Q2 2023 Earnings Conference Call October 28, 2022 09:00 ET Company Participants Amit Agarwal - Head of Investor Relations & Director of Finance Parag Agarwal - Chief Financial Officer Erez Israeli - Chief Executive Offic...
Dr. Reddy’s largest manufacturing facility in Bachupally, Hyderabad, joins Global Lighthouse Network of the World Economic Forum Journey started four years ago with digitisation of infrastructure and processes. Two years ago, Project ‘OpsNext’ ...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch, in the U.S. market, of Lenalidomide Capsules, a therapeutic equivalent generi...
U.S. biotech Intercept Pharmaceuticals ( NASDAQ: ICPT ) and India-based Dr. Reddy's Laboratories ( RDY ) have reached an agreement to settle a lawsuit over Dr. Reddy's plans to market a generic version of Intercept's ( ICPT ) liver disease therapy Ocaliva. The farnes...
Generic drugmakers Teva Pharmaceutical Industries ( NYSE: TEVA ) and Perrigo Company ( PRGO ) traded sharply lower on Wednesday after Bloomberg reported that the companies settled a lawsuit over the claims related to heartburn medication Zantac. Teva ( TEVA ) has rec...
Today, we revisit fast evolving biopharma name Eton Pharmaceuticals for the first time since October of last year. Since then, the company has launched several key products and made a key divestiture. What is ahead for this intriguing small cap concern? An investment analysis...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com We’re starting off the last day of trading this week with a breakdown of the biggest pre-market stock movers for Friday! Earnings reports, sale rumors, and an offer to t...
The shares of Athenex Inc. ( NASDAQ: ATNX ) climbed ~70% on rising volumes in the post-market Thursday in reaction to reports that India’s Dr Reddy's Laboratories ( RDY ) and Intas Pharmaceuticals are in talks to acquire the cancer-focused biotech. The compa...
Dr. Reddy's has launched multiple drugs in the US market recently which are expected to drive significant growth. The launch of bortezomib drug to give the company access to $1.2 billion myeloma treatment market. I assign a Hold rating for RDY after taking into consideration all t...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with pro...